Pharmacy Laws and Regulations: Kansas State Board of Pharmacy: Updated June 2023 - Couverture souple

State Board Of Pharmacy, Kansas

Couverture souple

ISBN 13 : 9798851757051

Editeur : Independently published, 2023

Synopsis

65-1625. Title of act. This act shall be known and may be cited as the pharmacy act of the state of Kansas. History: L. 1953, ch. 290, § 2; L. 1975, ch. 319, § 1; July 1. 65-1626. Definitions. As used in the pharmacy act of the state of Kansas: (a) "Address" means, with respect to prescriptions, the physical address where a patient resides, including street address, city and state. (b) "Administer" means the direct application of a drug, whether by injection, inhalation, ingestion or any other means, to the body of a patient or research subject by: (1) A practitioner or pursuant to the lawful direction of a practitioner; (2) the patient or research subject at the direction and in the presence of the practitioner; or (3) a pharmacist as authorized in K.S.A. 65-1635a, and amendments thereto, or K.S.A. 2022 Supp. 65-16,129, and amendments thereto. (c) "Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, repackager, wholesale distributor, third-party logistics provider or dispenser but does not include a common carrier, public warehouseman or employee of the carrier or warehouseman when acting in the usual and lawful course of the carrier's or warehouseman's business. (d) "Automated dispensing system" means a robotic or mechanical system controlled by a computer that: (1) Performs operations or activities, other than compounding or administration, relative to the storage, packaging, labeling, dispensing or distribution of drugs; (2) collects, controls and maintains all transaction information; and (3) operates in accordance with the board's rules and regulations. (e) "Biological product" means the same as defined in 42 U.S.C. § 262(i), as in effect on January 1, 2017. (f) "Board" means the state board of pharmacy created by K.S.A. 74-1603, and amendments thereto. (g) "Brand exchange," in the case of a drug prescribed, means the dispensing of a different drug product of the same dosage form and strength and of the same generic name as the brand name drug product prescribed, and in the case of a biological product prescribed, means the dispensing of an interchangeable biological product. (h) "Brand name" means the registered trademark name given to a drug product by its manufacturer, labeler or distributor. (i) "Co-licensed partner" means a person or pharmaceutical manufacturer that has entered into an agreement with another pharmaceutical manufacturer or an affiliate of the manufacturer to engage in a business activity or occupation related to the manufacture or distribution of a product. (j) "Common carrier" means any person who undertakes, whether directly or by any other arrangement, to transport property, including drugs, for compensation. (k) (1) "Compounding" means the combining of components into a compounded preparation under either of the following conditions: (A) As the result of a practitioner's prescription drug order or initiative based on the practitionerpatient-pharmacist relationship in the course of professional practice to meet the specialized medical need of an individual patient of the practitioner that cannot be filled by an FDA-approved drug; or (B) for the purpose of, or incidental to, research, teaching or chemical analysis, and not for sale or dispensing.

Détails de l'édition

• Éditeur: Independently published
• Date d'édition: 2023
• Langue: anglais
• ISBN 13: 9798851757051
• Reliure: Broché
• Nombre de pages: 348
• Coordonnées du fabricant: Manufactured by Amazon on behalf of the author; https://www.amazon.fr/hz/contact-us; ; c/o Amazon Media EU S.à.r.l., 38 Avenue John F. Kennedy; Luxembourg; L-1855; Luxembourg